Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelin-1: the yin and yang on vascular function.

Flora Linda Marasciulo1, Monica Montagnani, Maria Assunta Potenza

  • 1Department of Pharmacology and Human Physiology, Medical School - University of Bari, Italy.

Current Medicinal Chemistry
|June 22, 2006
PubMed
Summary

Endothelin-1 (ET-1), a vasoconstrictor, is implicated in hypertension. Imbalances in ET-1 and nitric oxide (NO) contribute to endothelial dysfunction, making ET-1 receptors therapeutic targets.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eosinophil-linked pulmonary circulation in EGPA Improves under anti-IL-5/R therapy: A longitudinal study.

European journal of internal medicine·2026
Same author

Impact of remote monitoring on well-being, therapeutic adherence, and organ damage evaluation in hypertensive patients: the PROSIT study.

European heart journal. Digital health·2026
Same author

Late endocrine-metabolic complications in survivors of young adult and adult-onset cancers: comprehensive evaluation and strategies for management. An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical review.

Journal of endocrinological investigation·2025
Same author

Understanding the impact of antibiotic treatment on the diversity of gut microbiota species.

Expert review of anti-infective therapy·2025
Same author

Efficacy and Safety of Mepolizumab 300 mg in Eosinophilic Granulomatosis With Polyangiitis: A Meta-Analysis of Eight Retrospective Studies.

Allergy·2025
Same author

Vaccination of people with solid tumors and diabetes: existing evidence and recommendations. A position statement from a multidisciplinary panel of scientific societies.

Journal of endocrinological investigation·2025

Area of Science:

  • Vascular Biology
  • Endocrinology
  • Cardiovascular Research

Background:

  • Endothelin-1 (ET-1) is a potent vasoconstrictor produced by endothelial cells, counterbalancing nitric oxide (NO).
  • ET-1 regulates vascular tone and cell proliferation via ETA and ETB receptors, with its release influenced by various physical and chemical stimuli.
  • Endothelial dysfunction, characterized by decreased NO bioavailability and increased ET-1 activity, is an early sign of vascular abnormalities and contributes to hemodynamic disorders.

Purpose of the Study:

  • To review the role of ET-1 in experimental hypertension.
  • To discuss the involvement of MAPK signaling pathways in ET-1 release in hypertension with insulin resistance.
  • To explore therapeutic applications of ET-1 receptor antagonists.

Main Methods:

Related Experiment Videos

  • Literature review of ET-1's role in experimental hypertension.
  • Summary of recent findings on MAPK signaling in ET-1 release.
  • Discussion of clinical applications of ET receptor blockers.

Main Results:

  • Dysregulation of the endothelin system is a key factor in cardiovascular disease pathogenesis.
  • MAPK signaling pathways are involved in ET-1 release in hypertension associated with insulin resistance.
  • ET receptor antagonists show potential as disease-modifying agents by preserving endothelial integrity.

Conclusions:

  • Imbalances in vasodilator (NO) and vasoconstrictor (ET-1) agents contribute to cardiovascular disease.
  • Targeting ETA and ETB receptors offers a promising therapeutic strategy for conditions with elevated ET-1.
  • ET receptor antagonists may help manage hypertension and preserve vascular health.